prnewswire.com
Negativewww.prnewswire.com ·
acurx pharmaceuticals inc reports first quarter 2026 results and provides business update 302765686
LEADERTAX_FNCACT_PRESIDENTIDEOLOGYTAX_DISEASE_INFECTIOUS
Topic context
This topic has been covered 354354 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedAcurx Pharmaceuticals is a clinical-stage biotech developing antibiotics. The news covers Q1 2026 financials, a new patent, and trial initiation for ibezapolstat. No commercial product revenue yet; impact is limited to the company's stock and funding runway. No direct commodity or supply chain effects.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Cash position $9.3M (up from $7.6M at end 2025)
- New patent for DNA pol IIIC inhibitors until Dec 2039
- Initiated clinical trial for ibezapolstat (IBZ) targeting rCDI
- Closed direct offering of 825,085 shares at $3.03 each
- Net loss $1.7M (improved from $2.1M loss year ago)
Related stories
finance.yahoo.com
zillow zg q1 2026 earnings 225404880
pharmiweb.com
celanese corporation reports first quarter earnings
baptistnews.com
something awful is happening in sudan and you dont know it
aktuality.sk
den vitazstva v tieni strachu putin oslavoval bez techniky a v obave z atentatu 217 tyzden vojny
nytimes.com